After the transplant, the treatment is given over about one year. One group receives a reduced dose of the immune-suppressing medicine, while the other group receives the standard dose. During the study, the health of the transplanted kidney is followed, and the study team looks for signs of rejection, infection, kidney function changes, and other serious problems. A biopsy, which is a small sample taken from the kidney, may be used to check for rejection.

The study also looks for dnDSAs, which are new antibodies made by the body against the transplanted kidney, and eGFR, a blood test that helps show how well the kidney is working. Other terms used in the study include ddcfDNA, a small amount of DNA from the transplanted kidney that can be found in the blood, and dialysis, a treatment that replaces some kidney function if the transplant stops working.

During the study, participants who have received a kidney transplant will be given their own immune cells that have been specially processed in a laboratory. These cells, called regulatory T cells, are part of the body’s natural system for controlling immune responses. The researchers will monitor the safety of this treatment and how well it works with regular check-ups and tests over approximately 60 weeks.

Other medications that may be used during the study include sulfamethoxazole and trimethoprim to prevent infections, valganciclovir for viral infections, and medications like paracetamol and dimetindene to manage side effects. The study will track any complications, infections, or rejection episodes that occur, as well as how well the transplanted kidney is working.

Participants will be assigned to receive either dapagliflozin or a placebo in the form of an oral tablet. Throughout the study, various health factors will be monitored, such as eGFR, which is a measure used to check how well the kidneys are filtering blood, and proteinuria, which is the presence of excess protein in the urine. Other areas of interest include monitoring creatinine levels, a waste product in the blood that indicates kidney health, and checking for cholesterol levels. The study will also track blood pressure, the force of blood against artery walls, and the occurrence of any urinary tract infection.

The research will continue for a set period to observe changes in health outcomes. This includes monitoring for kidney transplant rejection, where the body’s immune system attacks the new organ, and checking for end-stage renal disease, a condition where the kidneys can no longer support the body’s needs. Additionally, the study will track major adverse cardiac events, which are serious heart-related problems, and general safety through the reporting of adverse events. The participants will receive regular follow-ups to ensure all necessary measurements are taken over the course of the trial.

The purpose of the study is to determine if the generic versions of these medications work in the same way as the brand-name versions in kidney transplant patients. During the study, participants will take both generic and brand-name versions of their regular medications at different times. The medications will be given as oral capsules or tablets twice daily.

The study will last for 2 months, during which time researchers will monitor how the medications are processed by the body. This involves measuring the amount of medication in the blood at various times after taking the doses. The study will also look at how the medications interact with bacteria in the digestive system and how they are converted in the body.

The study will use various immunosuppressive medications including sirolimus, ciclosporin, tacrolimus, mycophenolic acid, azathioprine, prednisone, hydrocortisone, mycophenolate mofetil, everolimus, and methylprednisolone. These medications are commonly used to prevent organ rejection in transplant patients but may need adjustment during severe infections.

The research will track how well patients’ organs function over time and monitor for any signs of transplant rejection. Doctors will check kidney function through blood tests and measure how well other organs are working. Patients will be followed for 6 months after leaving the ICU to check their recovery and ensure their transplanted kidney continues to function properly.

The purpose of the study is to compare two different approaches to preventing CMV infection in kidney transplant recipients. One approach is called immune-guided prophylaxis, which involves using the body’s immune response to guide treatment. The other approach is preemptive therapy, which means starting treatment as soon as early signs of infection appear. The study will monitor the effectiveness and safety of these approaches over time.

Participants in the study will be observed for up to 12 months after their kidney transplant. The study will look at how many patients develop CMV disease and how many experience a condition called neutropenia, which is a low level of a type of white blood cell that helps fight infections. The study will also track the number of days patients take Valganciclovir and any side effects that occur. The goal is to determine which approach provides better outcomes for patients, with a focus on preventing CMV disease without causing neutropenia.

The study compares two different medications used to prevent rejection of the transplanted kidney. The first medication is belatacept, which is given through an intravenous injection, combined with standard treatment. The second medication is tacrolimus, which is taken as oral capsules, also combined with standard treatment. The purpose is to determine which medication works better in treating rejection when these new antibodies are detected.

The treatment period lasts for 12 months, during which patients will receive either belatacept or tacrolimus. Throughout the study, doctors will monitor how well the kidney is working by checking kidney function through blood tests and examining small samples of kidney tissue. They will also track the levels of antibodies in the blood and watch for any side effects of the medications.

The study will take place over a period of 18 months. During this time, participants will take the medication or placebo orally in the form of film-coated tablets. The study will monitor the function of the transplanted kidney by measuring a specific marker called eGFR, which stands for estimated glomerular filtration rate. This marker helps assess how well the kidneys are filtering waste from the blood.

Throughout the study, participants will have regular check-ups to monitor their health and the function of their transplanted kidney. The study aims to provide valuable information on whether Forxiga can be a safe and effective treatment option for improving kidney function in non-diabetic kidney transplant recipients. Participants will be closely monitored for any side effects or changes in their health during the study period.

The study involves patients who have End-Stage Kidney Disease and require dialysis before their transplant. These patients will be receiving kidneys from deceased donors through either Donation after Circulatory Death or Donation after Brain Death. The treatment involves receiving either ravulizumab or placebo through an intravenous infusion. The medication or placebo will be given to patients who meet specific medical requirements determined by their healthcare providers.

The study will track how long patients need to remain on dialysis after their transplant and monitor their kidney function. Researchers will observe patients for 90 days after their transplant to evaluate how well the treatment works. During this time, they will measure how quickly patients can stop requiring dialysis and how well their new kidney functions.

The purpose of the study is to compare the effectiveness of this new treatment with the standard care currently used for kidney transplant patients. Participants in the study will be divided into three groups, with some receiving the MIC treatment and others receiving the standard care. The study will monitor how well the new treatment helps the body accept the new kidney without causing rejection or other complications.

Throughout the study, participants will be closely observed for any side effects or reactions to the treatment. The study will also track the overall health of the kidney transplant, including any signs of rejection or infection, and the general well-being of the participants. The goal is to determine if the MIC treatment can provide a better outcome for kidney transplant patients compared to the current standard treatments.

Participants in the study will be given different formulations of Mycophenolate Mofetil, including both generic and brand-name versions, to see if there are any differences in how the body absorbs them when taken with Pantoprazole. The study will compare these formulations to determine if they are bio-equivalent, meaning they work in the same way and provide the same benefits. The study will last for a short period, with participants taking the medications orally, which means by mouth.

The trial aims to provide valuable information on how these medications interact, which could help improve treatment for transplant patients. By understanding the influence of Pantoprazole on Mycophenolate Mofetil, healthcare providers can make better-informed decisions about medication management in post-transplant care. The study is expected to conclude by the end of 2025.

The medications used in this study are taken by mouth daily. Tacrolimus is a medication that helps prevent the body from rejecting the transplanted kidney by suppressing the immune system. The standard treatment includes two additional immune-suppressing medications: mycophenolate mofetil, which also helps prevent organ rejection, and prednisone, which is a steroid medication that reduces inflammation and suppresses the immune system.

The study will follow participants for three years after their kidney transplant. During this time, researchers will monitor the occurrence of infections, the function of the transplanted kidney, and how well patients feel overall. They will also check how well the transplanted kidney is working through regular medical tests and track any complications that may occur.

Participants in the study will receive either mannitol or a placebo, which is a substance with no active treatment, through an intravenous infusion. The study will monitor how quickly the transplanted kidney begins to function and will also look at other factors such as the occurrence of acute kidney graft rejection within three months and the kidney’s performance at different time points, including seven days, one month, and three months after the transplant.

The trial aims to provide valuable information on whether mannitol can be a beneficial treatment option for improving outcomes in kidney transplant patients. The study will be conducted over a period of time, with participants being closely monitored to assess the effectiveness and safety of the treatment. This research could potentially lead to better management strategies for patients undergoing kidney transplantation, ultimately improving their quality of life.

The purpose of the study is to observe the long-term outcomes in patients who have received a kidney transplant and are considered to be at low risk for immune system complications. These patients are being treated with a medication called tacrolimus, either alone or in combination with another drug called mycophenolate mofetil. The study will compare the survival of the transplanted kidney and the overall health of the patients under these different treatment plans.

Participants in the study will receive the Pneumovax 23 vaccine and their response to the vaccine will be measured at various points over several years. This includes checking the levels of antibodies, which are proteins made by the immune system to fight infections, at 3 and 5 years after the initial vaccination, and again after a booster shot given 5 years later. The study will also monitor other health aspects such as kidney function, patient survival, and any episodes of rejection or infections. This research aims to provide valuable information on how well the vaccine works in kidney transplant patients and how it might affect their long-term health.

The study will involve kidney transplant recipients who are not diabetic and have had their transplant for more than six months. Participants will be monitored to see how Jardiance affects the oxygen levels in different parts of the kidney, specifically the cortex and medulla, which are areas within the kidney. This will be done using a special imaging technique called MRI, which allows doctors to see inside the body without surgery. The study will also look at other factors such as blood flow to the kidney, blood sugar levels, blood pressure, and heart rate.

The trial is designed to be a crossover study, meaning that participants will receive both the medication and the placebo at different times during the study. This helps researchers compare the effects of the medication directly with the placebo. The study is expected to start recruiting participants in early 2025 and will continue until 2027. The findings from this study could provide valuable insights into how Jardiance affects kidney function in transplant recipients.

The purpose of the study is to determine if the dose of Envarsus can be reduced compared to Advagraf while still maintaining effective levels of tacrolimus in the body. Participants in the study will take one of these medications orally, and their tacrolimus levels will be monitored to ensure they remain within a therapeutic range. The study will also look at whether switching to Envarsus results in fewer pills to take, fewer side effects, and more consistent medication levels in the body.

Throughout the study, researchers will also explore if certain genetic factors, like the presence of the CYP3A5*1 allele, should be considered when prescribing these medications. The trial aims to provide insights into the best dosing strategies for patients who require higher doses of tacrolimus to prevent organ rejection. The study is expected to continue until early 2026.

The purpose of the study is to determine if treating these early borderline lesions with Grafalon can prevent or slow down the progression of more serious kidney damage over time. The study will compare this treatment to the usual care that patients receive after a kidney transplant. Participants in the study will be monitored for two years to see how their kidney function changes and whether the treatment helps maintain the health of the transplanted kidney.

Throughout the study, researchers will also look at other health factors, such as blood pressure, cholesterol levels, and the occurrence of diabetes after the transplant. The goal is to understand if the treatment with Grafalon can improve overall outcomes for kidney transplant patients by reducing the risk of further complications. This study is being conducted in multiple centers across Spain, and it aims to provide valuable insights into the management of kidney transplant patients with early borderline lesions.

Participants in the study will receive one of several forms of tacrolimus, including Conferoport, Tacrolimus STADA, Advagraf, Modigraf, Adoport, Envarsus, or Prograf. These medications are administered orally, either as capsules, tablets, or granules. Some participants may receive a placebo. The study will last for a maximum of 26 weeks, during which the effectiveness of the genetic testing strategy in achieving the desired levels of tacrolimus in the blood will be assessed.

The purpose of the study is to determine if using genetic information before the transplant can help in adjusting the tacrolimus dose more effectively, potentially improving outcomes for patients. The trial will also look at the cost-effectiveness of this approach, as well as monitor for any side effects or adverse events related to the treatment. The ultimate goal is to enhance the safety and effectiveness of tacrolimus therapy in kidney transplant patients.

The purpose of the study is to evaluate the safety of the Eight Treg treatment when used alongside these standard medications. Participants will receive the Eight Treg infusion the day before their kidney transplant. The study will monitor participants for up to three months after the transplant to check for any side effects or complications. The study will also look at how the treatment affects the immune system and the new kidney over time.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the function of their new kidney. These tests will include blood tests and possibly biopsies of the kidney to ensure everything is working as expected. The study aims to provide valuable information on how well the Eight Treg treatment works in helping kidney transplant patients and how safe it is to use with other medications.

The purpose of the study is to see how taking eplerenone for 36 weeks affects the heart health of kidney transplant patients. Participants will be randomly assigned to receive either eplerenone or a placebo. The study will monitor changes in heart structure and function using echocardiograms, which are ultrasound tests of the heart. Researchers will also track any major heart-related events, such as heart failure or heart attacks, during the study period.

Throughout the study, participants will have regular check-ups to assess their heart health and overall well-being. The study will also measure blood pressure and levels of certain substances in the blood that indicate heart and kidney function. The goal is to determine if eplerenone can provide heart health benefits for patients who have received a kidney transplant and are on long-term calcineurin inhibitor therapy.

The study involves several medications used to suppress the immune system and prevent rejection of the transplanted kidney. These include Prednisone, a type of steroid taken orally; Basiliximab, also known as CHI-621, which is given through an intravenous injection; Tacrolimus, taken as a capsule; Mycophenolate Mofetil, also in capsule form; and Methylprednisolone, administered as an injection. Another medication used is Rabbit Anti-Human Thymocyte Immunoglobulin, which is given through an infusion. Some participants may receive a placebo instead of one of these medications.

Participants in the study will be randomly assigned to receive either the standard treatment or a personalized treatment plan based on their immunological risk, as determined by the biomarkers. The study will follow participants for two years to monitor outcomes such as kidney function, rejection episodes, and the development of antibodies. The study will also track other health aspects, including infections, metabolic disorders like diabetes, and any serious side effects related to the treatment. The aim is to improve the long-term success of kidney transplants by using a more individualized approach to immunosuppressive therapy.

Participants in the study will receive either Eplerenone or a placebo for four days before and immediately after their kidney transplant. The study will monitor various aspects of kidney health and overall well-being, including the clearance of a substance called Iohexol at three months, which helps assess kidney function. Other factors being observed include the need for dialysis, the occurrence of delayed graft function, protein levels in urine, and any episodes of high potassium levels, known as hyperkalemia, within the first week after the transplant.

The study will also track the length of the initial hospital stay, the survival rate of patients, and the kidney’s filtration rate over time, up to ten years after the transplant. Additionally, the occurrence of any acute rejection of the transplanted kidney will be recorded. This research aims to provide valuable insights into improving long-term outcomes for kidney transplant recipients.

Participants in this study will be taking eplerenone for a period of six months. During this time, researchers will monitor changes in the stiffness of the arteries, as well as other health indicators such as blood pressure and heart function. The study will also look at how the medication affects the overall health of the kidney transplant, including how well the kidney is working and any changes in blood markers that indicate stress or damage to the blood vessels.

The study is designed to provide valuable information on the potential benefits of eplerenone for kidney transplant patients, particularly in managing the health of their blood vessels and heart. By understanding these effects, the study aims to improve the long-term health outcomes for individuals who have received a kidney transplant. Participants will be closely monitored throughout the study to ensure their safety and to gather comprehensive data on the effects of the medication.

The purpose of the study is to investigate how the calcium supplement affects the way the body processes the medications tacrolimus and mycophenolate mofetil in people who have had a kidney transplant. Participants in the study will continue their regular medication regimen, which includes taking Prograf, CellCept, and Prednisolone, while also taking the calcium supplement. The study will monitor how these medications are absorbed and processed in the body over a period of time.

Throughout the study, participants will be asked to take their medications as prescribed and may be required to provide samples for analysis. The study aims to provide valuable information on the interaction between the calcium supplement and the immunosuppressive drugs used by kidney transplant recipients. This information could help improve treatment plans and outcomes for individuals who have received a kidney transplant.

The purpose of the study is to see if switching from anticalcineurins to Belatacept can improve the function of blood vessels in kidney transplant patients over a period of six months. Blood vessels are important for carrying blood throughout the body, and their ability to widen and narrow properly is a sign of good health. The study will involve regular check-ups and tests to monitor the health of the blood vessels and overall well-being of the participants.

Participants in the study will be divided into two groups. One group will continue their current treatment with anticalcineurins, while the other group will switch to Belatacept. The study will last for several months, during which time participants will receive their assigned treatment and undergo various assessments to track changes in their blood vessel function. The results will help determine if Belatacept offers any advantages over anticalcineurins in maintaining healthy blood vessels in kidney transplant patients.

Participants in the study will receive Grafalon® for a short period, and the effects will be monitored over time. The study will look at how the medication affects the immune system, particularly the levels of different types of blood cells, and will also track any side effects or adverse events that may occur. The study aims to find a dose that is effective in preventing complications without causing significant side effects.

Throughout the study, researchers will also observe the overall health of the participants, including their kidney function and any potential infections or other health issues that may arise after the transplant. The study will help to improve understanding of how to best use Grafalon® in kidney transplant patients to support their recovery and long-term health.

The purpose of this study is to determine if a lower dose of tacrolimus combined with everolimus works as well as the standard treatment using tacrolimus and mycophenolate mofetil in elderly transplant recipients. The study will monitor how well the transplanted kidney functions and track any complications that may occur over a two-year period after the transplant surgery.

During the study, participants will receive either the standard treatment or the new combination treatment. They will have regular check-ups to monitor their kidney function, measure drug levels in their blood, and assess their overall health. The study will track various aspects of the participants’ health, including kidney function, infections, diabetes, and quality of life.

The purpose of the study is to determine if adding tocilizumab to standard care treatment works better than standard care alone in preserving kidney function in transplant recipients who have this type of rejection. The medication will be given as a 162 mg injection under the skin for a period of 24 months.

During the study, participants will have their kidney function monitored through blood tests that measure how well their kidneys are filtering waste products from their blood. They will also have kidney tissue samples taken and undergo other medical tests to check their overall health and the condition of their transplanted kidney. The total duration of monitoring will last for 36 months, with regular check-ups to assess the kidney’s function and the participant’s general health.

Participants in the study will receive either Tacrolimus or mycophenolate mofetil, or a combination of both, as part of their regular treatment after a kidney transplant. The study will observe changes in the gut microbiota and how these changes might influence the effectiveness and processing of the medications. The study will also involve monitoring the participants over a period of time to gather data on how the medications are absorbed and metabolized in the body.

The study aims to provide insights into the variability of how different patients respond to these immunosuppressant drugs, which are crucial for the success of kidney transplants. By understanding these differences, the study hopes to improve treatment plans and outcomes for future patients undergoing kidney transplants. Participants will be monitored closely throughout the study to ensure their safety and to collect necessary data for the research.

The purpose of this research is to understand how these medications interact with the bacteria naturally present in the digestive system (known as the gut microbiome). The study will examine how these beneficial bacteria in the gut may affect the way the body processes these transplant medications. Participants will receive standard doses of both medications – up to 2000 mg per day of mycophenolate mofetil and up to 30 mg per day of tacrolimus.

The study will last for 12 months, during which researchers will monitor how the medications work in the body and how they affect the natural bacteria in the digestive system. Both medications will be taken by mouth. The medications used in this study are already approved for use in transplant patients and are part of standard care after kidney transplantation.

Participants in the study will receive the treatments and be monitored for their health and the function of their new kidney. The study will look at how well the treatments work in helping the body accept the new kidney and whether they can safely reduce the need for other medications that suppress the immune system. The study will also check for any changes in the immune system that might indicate a better acceptance of the new kidney.

The study will take place over several years, with regular check-ups to assess the health of the participants and the success of the kidney transplant. The goal is to find out if these treatments can help improve the outcomes for kidney transplant patients, making the process safer and more effective.

The study compares dapagliflozin with a placebo to determine if the medication can slow down the natural decline in kidney function that may occur after transplantation. The medication is taken as a film-coated tablet by mouth. The study will track how well the transplanted kidney functions over a period of three years.

During the study, participants will receive either dapagliflozin (10 mg daily) or a placebo. The kidney function will be monitored through regular blood tests that measure how well the kidney filters waste products from the blood. The study will also look at other aspects of health, including blood pressure, body composition, and the overall safety of the treatment in transplant recipients.

The purpose of the study is to compare the effectiveness of the shorter and longer antibiotic treatments. Participants will be randomly assigned to receive either a 7-day or a 14-day course of antibiotics. The study will monitor the participants’ health and recovery over a period of time to assess the effectiveness of the treatment. This will include checking for the resolution of symptoms such as fever and urinary tract infection signs, as well as ensuring no additional antibiotic treatment is needed up to 30 days after the initial treatment.

Throughout the study, participants will be observed for any potential side effects from the antibiotics and their overall kidney function will be assessed. The study will also track the incidence of any relapse or recurrence of the infection, as well as the presence of antibiotic-resistant bacteria. The goal is to ensure that the shorter treatment is not less effective than the longer one, potentially leading to a change in standard treatment practices for kidney transplant recipients with acute pyelonephritis.

In this study, children will receive one of several forms of tacrolimus, including PROGRAF capsules, Modigraf granules for oral suspension, and Envarsus prolonged-release tablets. These medications are all taken by mouth. The goal is to find the best way to give tacrolimus so that it works effectively and safely for each child. The study will monitor how well the children maintain the right levels of tacrolimus in their blood, especially in the first few days after their kidney transplant.

The purpose of the study is to improve the way tacrolimus is given to children who have had a kidney transplant, making it more tailored to their individual needs. This approach hopes to ensure that each child receives the most effective dose with the least risk of side effects. The study will last for a period of time, during which the children will be closely observed to see how well the personalized dosing works for them.

Participants in the study will be randomly assigned to one of two groups. One group will receive Rituximab, which is a type of medication known as a monoclonal antibody that targets specific cells in the immune system. The other group will receive a placebo. The study will monitor the participants over a period of time to observe the incidence of EBV infection and PTLD, as well as other health outcomes related to the transplant.

The study will track various health indicators over several years, including the presence of EBV in the blood, kidney function, and any other infections or complications that may arise. The aim is to gather information on how effective Rituximab is in preventing these issues in kidney transplant patients who are at risk of EBV infection. This research could provide valuable insights into improving the care and outcomes for transplant recipients.

The purpose of the study is to find the best dose of enoxaparin sodium for children who have had a kidney transplant. The study will use a special method to adjust the dose, aiming to achieve the right level of medication in the blood. This is important to ensure the medication is effective in preventing clots without causing side effects. The study will involve children aged 2 to 18 years who have been identified by their transplant team as needing this treatment.

Participants in the study will receive enoxaparin sodium through a small injection under the skin. The treatment will last for up to seven days, and the effectiveness of the dose will be checked by measuring specific activity levels in the blood. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study aims to improve the care and outcomes for children undergoing kidney transplants by optimizing their treatment with enoxaparin sodium.

Participants in the study will receive the treatment through an intravenous injection, which means it will be administered directly into a vein. The study will monitor the patients over a period of time to see how well the treatment works in preventing the infection. The researchers will check the levels of the virus in the blood and urine at various points after the transplant, as well as monitor the patients’ immune response to the virus.

The study will also look at other factors, such as the health of the transplanted kidney and the overall well-being of the patients over the course of a year. This includes checking for any side effects from the treatment and ensuring the patients’ bodies are accepting the new kidney. The goal is to gather information that could help improve the care and outcomes for kidney transplant patients in the future.

Participants in the study will be randomly assigned to one of two groups. One group will continue taking their immunosuppressant medication, while the other group will stop taking it after six months. The study will last for 24 months, during which time the participants’ immune response will be monitored to see if there is a difference in the level of HLA sensitization between the two groups. This will help determine if it is safe to stop taking immunosuppressants after a certain period without increasing the risk of the body developing a reaction against the kidney transplant.

The study aims to provide valuable information on the management of immunosuppressant therapy in patients with late renal graft failure. By understanding the effects of continuing versus stopping these medications, the study hopes to improve the long-term outcomes for patients who have undergone kidney transplantation. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatment strategies being tested.

The purpose of the study is to see if using GLP-1 receptor agonists right after a kidney transplant can prevent the development of diabetes in people who are at high risk. Participants in the study will receive either the medication or a placebo. The study will follow participants for a period of up to 12 months, with regular check-ups to monitor their health and any changes in their condition. During these visits, various health indicators such as blood sugar levels, weight, and kidney function will be assessed.

This trial aims to provide valuable information on whether early treatment with Trulicity can help prevent diabetes in kidney transplant recipients. The study will also look at other health factors, including the need for additional diabetes medications, changes in body weight, and overall kidney health. The results could lead to better management strategies for preventing diabetes in people who have undergone a kidney transplant.

The purpose of the study is to see if treatment with Trulicity can help reverse metabolic syndrome in these patients. The study will last for up to six months, during which participants will receive the medication as an injection. The researchers will check the participants’ health status at three and six months to see if there are improvements in their metabolic syndrome. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, the researchers will monitor various health indicators, such as blood sugar levels and body weight, to assess changes in the participants’ conditions. They will also keep track of any side effects, such as nausea, diarrhea, or headaches, and any changes in insulin sensitivity, which is how well the body responds to insulin. The study aims to provide valuable information on whether Trulicity can be an effective preventive treatment for diabetes in patients awaiting kidney transplants.